-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Prime Medicine to Neutral, Lowers Price Target to $1.5

Benzinga·05/27/2025 12:35:58
Listen to the news
Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral and lowers the price target from $10 to $1.5.